Background
Adalimumab is a biologic medicine that blocks tumor necrosis factor alpha (TNF-α), a key inflammatory signal in many autoimmune diseases. It is widely used for conditions such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, axial spondyloarthritis, and several eye-related inflammatory disorders. Although adalimumab can be highly effective, some patients develop anti-adalimumab antibodies (AAA). These antibodies can reduce drug levels, lower treatment response, and sometimes lead to loss of disease control.
Therapeutic drug monitoring, which includes checking adalimumab concentration and AAA status, may help clinicians understand why a patient is not responding as expected. However, the risk factors for developing AAA are not fully understood. This study focused on whether ocular inflammation itself, often a sign of active autoimmune disease, is associated with a higher chance of AAA formation.
Study Design and Methods
This was a retrospective case-control study using the Stanford Research Repository (STARR), a clinical data warehouse that combines electronic health records from Stanford Health Care, Stanford Children’s Health, and affiliated clinics. Researchers reviewed patients treated with adalimumab for at least six months between June 2005 and May 2024 and who had testing for adalimumab level and/or anti-adalimumab antibodies.
The team collected demographic information, autoimmune diagnoses, eye involvement, and prior or concurrent treatments. They then used univariate and multivariable logistic regression to identify factors linked to AAA development.
The main outcomes were the relationship between AAA and ocular inflammation, as well as the proportion of AAA-positive patients in the cohort.
Key Findings
A total of 704 patients met the study criteria. Of these, 151 patients, or 21.5%, developed anti-adalimumab antibodies. AAA positivity was more common in females than in the AAA-negative group, with 60.9% versus 47.0% female representation. After adjustment for other factors, female sex remained independently associated with AAA development.
The strongest clinical association in the study was ocular inflammation. Patients with eye inflammation had a significantly higher risk of developing anti-adalimumab antibodies, even after adjustment for other variables. In multivariable analysis, ocular inflammation had an adjusted odds ratio of 2.19, meaning the odds of AAA formation were more than twice as high in patients with ocular involvement.
Other independent risk factors included interruption of adalimumab therapy, which also increased the likelihood of antibody formation. On the other hand, prior use of biologic therapy other than TNF-α inhibitors appeared protective. Prior exposure to another TNF-α inhibitor was associated with a higher risk.
Interpretation of the Results
These findings suggest that ocular inflammation may be a marker of a more immunologically active or difficult-to-control autoimmune disease state, which in turn may increase the chance that the body develops antibodies against adalimumab. Another possible explanation is that patients with ocular disease may experience more treatment interruptions, dose changes, or incomplete inflammatory control, all of which can contribute to immunogenicity.
The results also align with previous knowledge that biologic therapies are more likely to trigger antibody formation when drug exposure is inconsistent or when the immune system is highly activated. Interruption of treatment may allow the immune system to recognize the biologic as a foreign protein and mount an antibody response.
The protective association seen with prior non-TNF biologic therapy may reflect differences in immune modulation, disease history, or treatment selection patterns. However, because this was a retrospective study, the exact causal mechanism cannot be proven from the data alone.
Clinical Significance
This study has important implications for both ophthalmologists and rheumatology or internal medicine clinicians who prescribe adalimumab. Patients with ocular inflammation may benefit from closer follow-up, earlier therapeutic drug monitoring, and careful attention to adherence and continuity of therapy.
If a patient develops worsening eye inflammation or shows signs that adalimumab is no longer working well, checking drug levels and AAA could help determine whether the problem is underdosing, antibody-mediated loss of response, or another cause. In some cases, treatment adjustments may include optimizing dosing, reducing unnecessary interruptions, switching to another biologic, or adding an immunomodulator when appropriate.
The study also reinforces the importance of coordination between eye specialists and systemic disease specialists. Ocular inflammation can be both a target and a clue: it may need direct treatment, but it may also signal a broader systemic inflammatory process that affects biologic response.
What the Numbers Mean
A key takeaway is that more than one in five patients in this cohort developed anti-adalimumab antibodies. That is a clinically meaningful proportion. It suggests that immunogenicity is not a rare event in long-term adalimumab use among patients with autoimmune disease.
The adjusted odds ratios in the study indicate relative risk after accounting for other variables. For example, an adjusted odds ratio of 2.19 for ocular inflammation means that, all else being equal, the odds of AAA development were significantly higher in patients with eye inflammation than in those without it. While odds ratios do not directly equal absolute risk, they are useful for comparing factors that may influence antibody formation.
Limitations
As with many retrospective studies, there are limitations. The study relied on existing medical records, which may contain missing data or incomplete documentation. Testing for adalimumab levels and AAA was likely performed more often in patients with suspected treatment failure, which could introduce selection bias.
In addition, the study design shows association, not causation. Ocular inflammation may be a true risk factor, but it may also be a marker for other unmeasured factors such as disease severity, medication adherence, or treatment history. The study was also conducted in a single health system, so results may not fully generalize to all patient populations.
Practical Takeaways
For patients receiving adalimumab, especially those with autoimmune eye inflammation, several practical points stand out:
1. Regular follow-up matters, because loss of response can develop over time.
2. Treatment interruptions should be avoided when possible, since they may increase antibody risk.
3. If symptoms worsen or improvement stalls, therapeutic drug monitoring can be helpful.
4. Eye inflammation may indicate a higher likelihood of anti-drug antibody formation and may justify closer monitoring.
5. Shared care between ophthalmology and rheumatology or other relevant specialties can improve outcomes.
Conclusion
This study found that ocular inflammation is independently associated with a higher risk of anti-adalimumab antibody formation in patients with autoimmune diseases treated with adalimumab. Female sex and interruption of therapy also increased the risk, while prior treatment with a non-TNF biologic appeared protective. More than 20% of patients in the cohort developed AAA.
Overall, the findings support the idea that therapeutic drug monitoring may be especially valuable in patients with autoimmune eye disease. By identifying antibody formation early, clinicians may be able to adjust therapy sooner, preserve treatment effectiveness, and better control both ocular and systemic inflammation.
